Cytotoxic effect of Eudragit L-100 nanoparticle-based cisplatin on lung cancer

Purpose: To develop Eudragit L-100 nanoparticle-based cisplatin (Cis) and determine its cytotoxicity effect against lung cancer. Methods: Eudragit L-100 nanoparticles (NPs) were prepared using the double-emulsion solvent evaporation method. Morphology, size, polydispersity index, zeta potential, drug encapsulation efficiency, and in vitro drug release in phosphate-buffered saline (pH 7.4) were investigated. Results: Cis-loaded NPs' cytotoxicity was higher than free drugs against lung cancer cells (p < 0.05). Moreover, cis-loaded nanocarriers inhibited NCI-H60 lung carcinoma cells using the MTT assay in a dose-dependent manner. Conclusion: Eudragit L-100 NPs-based cisplatin exhibits a promising carrier system for effectively delivering chemotherapeutic agents targeting lung cancer. Further studies should focus on optimizing formulation parameters, conducting comprehensive pharmacokinetic and mechanistic studies, and evaluating therapeutic efficacy and safety in preclinical models.